STOCKHOLM, Sweden, 6 May 2021: Today, Lipidor AB (publ) (Nasdaq First North: LIPI) publishes its interim report for the period January – March 2021. The quarterly report is available on the company's website (click here (https://lipidor.se/lipidor-ab-delrsrapport-q1-2021/)) and in the attached pdf (in Swedish). Summary of the interim report – first quarter 2021 The period began with a […]
STOCKHOLM, den 6 maj 2021: Idag publicerar Lipidor AB (publ) (Nasdaq First North: LIPI) sin delårsrapport för perioden januari – mars 2021. Kvartalsrapporten finns att hämta på bolagets hemsida (klicka här (https://lipidor.se/lipidor-ab-delrsrapport-q1-2021/)) samt i form av bifogad pdf. Sammanfattning av delårsrapporten – första kvartalet 2021 Perioden inleddes med ett undertecknat licensavtal med Cannassure Therapuetics Ltd. avseende medicinska cannabisprodukter […]
Stockholm, Sweden, 23 April 2021 – Lipidor AB (publ) (Nasdaq First North: LIPI) today announces that the company will publish its annual report for the financial year 2020. The annual report (in Swedish) is available on the company's website lipidor.se (https://lipidor.se/lipidor-ab-rsredovisning-2020/) and in the attached pdf. The information was submitted for publication, through the office of […]
Stockholm den 23 april 2021 – Lipidor AB (publ) (Nasdaq First North: LIPI) meddelar idag att bolaget publicerar sin årsredovisning för verksamhetsåret 2020. Årsredovisningen finns att hämta på bolagets hemsida lipidor.se (https://lipidor.se/lipidor-ab-rsredovisning-2020/) samt i form av bifogad pdf. Informationen lämnades, genom nedanstående kontaktpersons försorg, för offentliggörande den 23 april 2021 kl. 12.00 CEST. För ytterligare information vänligen kontakta […]
Stockholm, 23 February 2021: Today, Lipidor AB publishes its year-end report for the period 1 January – 31 December 2020. The report is available on the company's website lipidor.se (https://lipidor.se/lipidor-ab-bokslutskommunik-2020/) and in the attached pdf. Summary of quarterly report – Q4 2020 A quarter of high activity and more important milestones including: redemption of warrants amounting […]
STOCKHOLM, den 23 februari 2021: Idag publicerar Lipidor AB sin bokslutskommuniké för perioden 1 januari – 31 december 2020. Bokslutskommunikén finns att hämta på bolagets hemsida lipidor.se (https://lipidor.se/lipidor-ab-bokslutskommunik-2020/) samt i form av bifogad pdf. Sammanfattning av delårsrapporten – fjärde kvartalet 2020 Ett kvartal med hög aktivitet och fler viktiga milstolpar inklusive: inlösen av teckningsoptioner om 20 MSEK, rekryterat […]
STOCKHOLM, Sweden, 18 January 2021 – Lipidor AB (Nasdaq First North:LIPI) today announced that the Company has signed an exclusive licensing agreement with Cannassure Therapeutics Ltd. (TASE:CSURE), an Israeli company specializing in the development and manufacture of innovative medicinal cannabis products. Under the agreement, Cannassure has the exclusive right to use Lipidor's proprietary drug delivery […]
STOCKHOLM den 16 december 2020 – Lipidor AB (Nasdaq First North:LIPI) meddelar idag att bolaget har tecknat ett nytt samarbetsavtal med Aurena Laboratories AB. Under en femårsperiod kommer Lipidor att investera upp till 15 MSEK i det nya samarbetet. Avtalet innebär att Aurena Laboratories bygger upp en produktionsenhet som kommer uppfylla de regulatoriska kraven för […]
STOCKHOLM, Sweden, 16 December 2020 – Lipidor AB (Nasdaq First North:LIPI) announced today that the Company has signed a new cooperation agreement with Aurena Laboratories AB. Over a five-year period, Lipidor will invest up to SEK 15 million in the new collaboration. Under the agreement, Aurena Laboratories will establish a production unit to meet the […]
STOCKHOLM, 19 August 2020: Today, Lipidor AB publishes its interim report for the period July – September 2020. The quarterly report is available on the company's website lipidor.se (https://lipidor.se/investors/financial-reports/interim-reports/) and in the attached pdf. Summary of the interim report – third quarter 2020 A quarter of high activity and many important milestones, including: a directed share […]